Track & Trace – And Delay: Pharmacies Get Enforcement Discretion From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's grace period for transaction information sharing means that distribution channels will operate more smoothly, but also could result in more missed deadlines down the road.
You may also be interested in...
Track And Trace Deadline Could Slip Again After Worries Over Inferencing
Generic representative raises concerns about errors from bulk scanning, while distributors and pharmacies feel failure to include inferencing will hinder patient access to drugs.
Drug Shortages Mostly FDA’s Fault, House Oversight Committee Concludes
Report says aggressive enforcement in recent years has forced capacity offline, which led to shortages.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.